Clinical and bacteriological efficacy of sequential intravenous to oral moxifloxacin in hospitalised patients with community-acquired pneumonia and pneumococcal bacteraemia
Abstract number: 1733_1517
Choudhri S., Arvis P., Haverstock D.
Objectives:Streptococcus pneumoniae is the leading bacterial pathogen in patients with community-acquired pneumonia (CAP) and the presence of pneumococcal bacteraemia in this setting is associated with significant morbidity and mortality. Pooled data from 6 CAP trials were used to compare the clinical and microbiological efficacy of sequential intravenous (IV)/oral (PO) moxifloxacin (MXF) with comparator (COMP) therapy in patients with pneumococcal bacteraemia.
Methods: Data were pooled from all 6 of the sequential trials carried out on 400 mg (IV/PO) MXF in the treatment of CAP in hospitalised patients. COMP treatment consisted of ceftriaxone + erythromycin, amoxicillin/clavulanate ± clarithromycin, trovafloxacin, levofloxacin, ceftriaxone ± azithromycin ± metronidazole or ceftriaxone + levofloxacin. All patients had blood cultures performed prior to initiation of study drug therapy. Severe CAP was defined using the modified ATS criteria.
Results: The 6 trials randomised 3015 patients (1494 MXF, 1521 COMP) of which 2288 were valid per protocol (PP) (1141 MXF, 1147 COMP). Of the valid PP patients, 342 MXF and 361 COMP-treated subjects were also microbiologically valid. Of these 178 (52.0%) MXF and 192 (53.2%) COMP-treated subjects had CAP due to S. pneumoniae with 48 (14.0%) MXF and 64 (17.7%) COMP patients having pneumococcal bacteraemia. Clinical and bacteriological success rates of MXF and COMP therapy in patients with pneumococcal bacteraemia.
Conclusions: Sequential therapy with IV/PO MXF resulted in higher clinical and bacteriological success rates than comparator therapy in patients with CAP associated with pneumocococcal bacteraemia, including patients with severe CAP.
Research funding: Bayer HealthCare Pharmaceuticals.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|